Patent ID: 8791163

Claim:
A composition comprising a compound of Formula I and a pharmaceutically acceptable excipient, wherein said composition is formulated for oral, transdermal, or parenteral administration, and wherein Formula I is or a pharmaceutically acceptable salt thereof, wherein: a) n is 1 or 2; b) m is 0, 1 or 2; c) p is 0, 1, 2, 3, 4, 5, 6, 7 or 8; d) v is 2 or 3; e) A is aryl or heteroaryl; f) Z is O, S or NR 8 ; g) Y is selected from the group consisting of hydrogen, aryl, heteroaryl, C 2 -C 6 alkyl, C 3 -C 6 cycloalkyl, and h) R is selected from the group consisting of hydrogen, hydroxyl, —OCF 3 , CF 3 , C 1 -C 8 alkyl, C 1 -C 8 alkyloxy, C 1 -C 8 alkylthio, halogen and —Z—(CH 2 ) p -A; i) R 1 is selected from the group consisting of C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, CF 3 , hydroxy-substituted C 1 -C 4 alkyl, hydroxy-substituted C 3 -C 6 cycloalkyl, and NHR 5 , wherein R 5 is C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl; j) R 2 is selected from the group consisting of: hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, OCF 3 , CF 3 , hydroxyl, and halogen; k) R 3 is selected from the group consisting of C 2 -C 4 alkyl, C 1 -C 4 alkyloxy, OCF 3 , CF 3 , hydroxyl, F, Br, and I; l) R and R 3 may be connected together to form an —O—(CH 2 ) v bridge representing with the carbon atoms to which they are attached a 5- or 6-membered heterocyclic ring system; m) R 4 is selected from the group consisting of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, OCF 3 , CF 3 , hydroxyl, and halogen; n) R 6 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl; o) R 7 is selected from the group consisting of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyloxy, OCF 3 , CF 3 , hydroxyl, and halogen; and p) R 8 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl, with the proviso that when a) Y is CH 3 , then R is OMe, OBu, OHex or O(CH 2 ) 4 Ph, R 1 is CH 3 , and R 6 is H, with the further proviso that when R is OMe then n is 2; b) R 3 is hydrogen, then R is hydrogen, OMe, Br, OBu, OHex or O(CH 2 ) 4 Ph, with the further proviso that when: i) R is hydrogen, then Y is Ph, n is 1, R 6 is H and R 1 is CH 3 ; ii) R is OMe, then Y is Ph, n is 1, R 6 is H and R 1 is CH 3 ; iii) R is OMe, then Y is 3-MeOPh, n is 1, R 6 is H and R 1 is CH 3 ; iv) R is Br, then Y is Ph, n is 1, R 6 is H and R 1 is CH 3 ; v) R is OMe, then Y is β-naphthyl; n is 1, R 6 is H and R 1 is CH 3 ; vi) R is O(CH 2 ) 4 Ph, then Y is Ph, n is 1, R 6 is H and R 1 is CH 3 ; vii) R is OMe, then Y is CH 2 Ph; n is 1, R 6 is H and R 1 is CH 3 ; ix) R is OMe, then Y is Ph; n is 1, R 6 is H and R 1 is Pr; x) R is OMe, then Y is Ph; n is 1, R 6 is H and R 1 is c-Bu; and xi) R is OMe, then Y is Ph; n is 1, R 6 is Me and R 1 is CH 3 ; and c) Y is Et, then R cannot be H, CH 3 , OMe or Et, wherein the compound of Formula I does not have structures where: R is OMe, R 3 is H, Y is H, n is 1, R 6 is H, and R 1 is CH 3 ; and R is H, R 3 is OMe, Y is H, n is 1, R 6 is H, and R 1 is CH 3 , and wherein the compound has antidepressant activity or sleep inducing properties.